Menu
Back to Journals » Clinical Ophthalmology » Volume 14
Outcomes of Pre-Early Treatment for Retinopathy of Prematurity (Pre-ETROP)
Authors Titawattanakul Y, Kulvichit K, Varadisai A, Mavichak A
Received 16 July 2020
Accepted for publication 24 September 2020
Published 16 October 2020 Volume 2020:14 Pages 3393—3397
DOI https://doi.org/10.2147/OPTH.S268997
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Yothin Titawattanakul, Kittisak Kulvichit, Adisai Varadisai, Apivat Mavichak
Vitreo-retina Research Unit, Department of Ophthalmology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
Correspondence: Kittisak Kulvichit
Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Tel +66 2 2564000
Email kulvichit@gmail.com
Introduction: The earlier treat stage 3 ROP is more likely to achieve better outcomes.
Primary Purpose: To study the unfavorable outcomes and regression after pre-early treatment for ROP.
Secondary Purpose: To evaluate the progression and recurrence of ROP requiring retreatment after pre-early treatment for ROP.
Patients and Methods: The data were retrieved retrospectively from the medical records of all infants who were screened and treated for ROP from January 2009 to January 2014 at a tertiary care facility. The outcomes measured the following: 1. unfavorable outcomes; 2. regression of ROP; 3. progression of ROP and 4. recurrence of ROP requiring retreatment. We treated all stage 3 ROP in any zone, with or without plus. The study also compared the outcomes between the pre-ETROP and the ETROP subgroups.
Results: There were 91 eyes with stage 3 ROP. Of the total of 91 eyes, there were 63 eyes with the pre-ETROP group and 28 eyes of the ETROP group. The unfavorable outcomes after treatment occur 6 eyes from 28 eyes (21.43%) in the ETROP group but no unfavorable outcomes in the pre-ETROP group (P=0.001). The pre-ETROP group who were treated with laser LIO alone had 100% regression, while the ETROP group who were treated with LIO (26 eyes) had 88.46% regression. There were 2 eyes of this group who were treated with a combination of LIO and IVT Bevacizumab. Both of them did not have regression. The recurrence of ROP requiring retreatment occurred in 2 eyes (7.14%) of the ETROP group, but no recurrence in the pre-ETROP group (P=0.092). The progression after treatment occurred in 3 eyes (10.71%) in the ETROP group, but no progression in the pre-ETROP group (P=0.027).
Conclusion: The pre-ETROP treatment is useful for reducing unfavorable outcomes and increasing the regression of ROP. Further, the treatment can reduce the recurrence of neovascularization and progression after treatment.
Keywords: retinopathy of prematurity, pre-early treatment for retinopathy of prematurity, outcomes, regression
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.